This suggested that addition of VPA could directly support innate anti-tumor immunity by increasing activating NK cell:tumor target interactions; this was subsequently confirmed because VPA treatment of melanoma cells prior to their co-culture with HSVGM-CSF-treated PBMCs caused increased NK cell-mediated tumor cell killing (Figure 4B). The gene discussed is CSF2; the disease is neoplasm.